Press Release
Press Release
Press Contacts: Erik Cummins, Matt Hyams, Olivia Thomas
02.25.21
Led by Silicon Valley-based Corporate partner Armando Castro, Pillsbury represented Cullgen Inc., a leading biotechnology company, on the closing of a $50 million Series B financing.
Including Cullgen’s existing investors, five new international venture capital firms participated in the financing, including the lead investor, 3E Bioventures Capital, Heights Capital Management (an affiliate of Susquehanna International Group), Octagon Capital, MSA Capital and South China Venture Capital.
The financing will support the development of Cullgen’s technology platform and internal pipeline of targeted protein degraders in oncology and other diseases.
Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches.
Read more about the transaction here.